Concomitant development of oral dyskinesia and memory deficits in reserpine-treated male and female mice

Behavioural Brain Research

Volumn 132, Issue 2, 2002, Pages 171-177

  Silva, Regina H ^a,b   Abílio, Vanessa C ^a   Torres Leite, Danila ^a   Bergamo, Marcelo ^a   Chinen, Cibele C ^a   Claro, Flávia T ^a   Carvalho, Rita De Cássia ^a   Frussa Filho, Roberto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SANTO AMARO   (Brazil)

Author keywords

Behavior; Gender; Memory; Mice; Reserpine; Tardive dyskinesia

Indexed keywords

RESERPINE; SODIUM CHLORIDE;

AMNESIA; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; COGNITIVE DEFECT; CONDITIONING; CONTROLLED STUDY; DIAGNOSTIC TEST; DISCRIMINATION LEARNING; DISEASE COURSE; DRUG EFFECT; FEMALE; MALE; MASTICATION; MAZE TEST; MEDICAL RECORD; MOUSE; MOVEMENT (PHYSIOLOGY); NONHUMAN; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; STATE DEPENDENT LEARNING; STIMULATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; COGNITION; DYSKINESIA, DRUG-INDUCED; FEMALE; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MOUTH; RESERPINE;

EID: 0037076459     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(01)00409-0     Document Type: Article

References (43)

1. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?
2. Effects of age on a new animal model of tardive dyskinesia
3. A study of facial dyskinesia in a mental hospital population
4. Tardive dyskinesia reversible and irreversible
5. Tardive dyskinesia - Pathophysiology
6. Persistent extrapyramidal side effects after long-term application of neuroleptics
7. Cognitive sequelae of tardive dyskinesia
8. Tardive dyskinesia
9. Modulation of emotional and non emotional memories: Same pharmacological systems, different anatomical systems
10. Oxygen radicals as key mediators in neurological disease: Fact or fiction?
11. Role of free radicals in aging and disease
12. Neuroleptic-induced oral movements in rats: Methodological issues
13. Oxygen free-radicals and neuropsychiatric illness
14. Is tardive dyskinesia a unique disorder?
15. Behavioural and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats
16. Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment
17. Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: Support for a model of tardive dyskinesia
18. Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia
19. Metals and free radicals in neurodegeneration
20. Tardive dyskinesia in Hungarian psychiatric wards
21. Effects of buspirone on an animal model of tardive dyskinesia
22. Reserpine does not induce orofacial dyskinesia in spontaneously hypertensive rats
23. Potent anitdopaminergic activity of oestradiol at the pituitary level on prolactin release
24. Factors influencing the prevalence and severity of tardive dyskinesia
25. Aging and tardive dyskinesia
26. Effects of long-term ganglioside GM1 administration on a new discriminative avoidance test in normal adult mice
27. The plus-maze discriminative avoidance task: A new model to study memory-anxiety interactions. Effects of chlordiazepoxide and caffeine
28. Spatial learning and memory deficits induced by dopamine administration with decreased glutathione
29. Tardive dyskinesia and psychotropic drug history
30. An assessment of tardive dyskinesia in schizophrenic outpatients
31. Acute reserpine administration elicits long-term spontaneous oral dyskinesia
32. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy
33. Effects of monosialoganglioside on a new animal model of tardive dyskinesia
34. Dyskinésie tardive postneuroleptique
35. Estrogens in tardive dyskinesia in male psychiatric patients
36. Psychopathologyical and cognitive correlates of tardive dyskinesia in schizophrenia and other disorders treated with neuroleptic drugs
37. Vulnerability to tardive dyskinesia in schizophrenia: An exploration of individual patient factors
38. Cognitive dysfunction, negative symptoms and tardive dyskinesia in schizophrenia: Their association in relation to topography of involuntary movements and criteriation of their abnormality
39. Cognitive dysfunction in schizophrenia: Organic vulnerability factor or state marker for tardive dyskinesia?
40. Cognitive deficits and tardive dyskinesia
41. Can supersensitivity of rodents to dopamine be regarded as a model of tardive dyskinesia?
42. Gender as a factor in the development of tardive dyskinesia
43. Prevalence of tardive dyskinesia in 3140 French inpatients